目的 探究非鳞非小细胞肺癌患者以常规化疗联合贝伐珠单抗的临床作用价值.方法 回顾性选取2020年6月—2023年6月福建省福州市长乐区医院胸外科收治的120例非鳞非小细胞肺癌患者的临床资料,根据不同治疗方法分为对照组和观察组,各60例.对照组行常规化疗方案(培美曲塞二钠+顺铂)治疗,观察组行常规化疗方案+贝伐珠单抗治疗,共治疗6个周期.分析两组的临床疗效、肿瘤标志物与T淋巴细胞亚群水平、不良反应.结果 观察组客观缓解率51.67%(31/60)、疾病控制率93.33%(56/60)均高于对照组的33.33%(20/60)、71.67%(43/60),差异有统计学意义(χ2=4.126、9.755,P均<0.05).入院时,两组患者的肿瘤标志物水平对比,差异无统计学意义(P>0.05).治疗6个周期后,观察组肿瘤标志物水平低于对照组,差异有统计学意义(P<0.05).入院时,两组患者的T淋巴细胞亚群水平对比,差异无统计学意义(P>0.05).治疗6个周期后,对照组患者的辅助性T淋巴细胞(cluster of differentiation 4,CD4+)、CD4+/抑制或杀伤性T淋巴细胞(cluster of differentiation 8,CD8+)水平均低于入院时,CD8+水平高于入院时,观察组CD4+、CD4+/CD8+水平均高于对照组,CD8+水平低于对照组,差异有统计学意义(P均<0.05).两组患者的不良反应发生情况对比,差异无统计学意义(P>0.05).结论 非鳞非小细胞肺癌患者在常规化疗的基础之上辅助运用贝伐珠单抗,可保证疗效得到提升,患者具备更低的肿瘤标志物水平,让机体具备更高的免疫功能.
Evaluation of the Effectiveness of Bevacizumab Adjuvan Conventional Chemotherapy in the Treatment of Non-squamous Non-small Cell Lung Cancer
Objective To explore the clinical value of conventional chemotherapy combined with bevacizumab in pa-tients with non-squamous non-small cell lung cancer.Methods The clinical data of 120 patients with non-squamous non-small cell lung cancer admitted to the Department of Thoracic Surgery in Changle District Hospital of Fuzhou City,Fujian Province from June 2020 to June 2023 were retrospectively selected.According to different treatment methods,they were divided into control group and observation group,with 60 cases in each group.The control group was treated with conventional chemotherapy regimen(pemetrexed disodium+cisplatin),and the observation group was treated with conventional chemotherapy regimen+bevacizumab,with a total of 6 treatment cycles.The clinical efficacy,tumor markers,T lymphocyte subsets and adverse reactions of the two groups were analyzed.Results The ob-jective remission rate was 51.67%(31/60)and disease control rate was 93.33%(56/60)in the observation group,which were higher than those in the control group 33.33%(20/60),71.67%(43/60),and the differences were statistically sig-nificant(χ2=4.126、9.755,both P<0.05).At admission,there was no significant difference in the levels of tumor mark-ers between the two groups(P>0.05).After 6 cycles of treatment,the level of tumor markers in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).On admission,there was no significant difference in the level of T lymphocyte subsets between the two groups(P>0.05).After 6 cycles of treatment,the levels of cluster of differentiation 4(CD4+)and CD4+/cluster of differentiation 8(CD8+)in the control group were lower than those at admission,and the level of CD8+was higher than that at admission,and the levels of CD4+and CD4+/CD8+in the observation group were higher than those in the control group,and the level of CD8+was lower than that in the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The adjuvant use of be-vacizumab on the basis of conventional chemotherapy in patients with non-squamous non-small cell lung cancer can ensure that the efficacy is improved,patients have lower tumor marker levels,and the body has higher immune func-tion.
NETL
NSTL
万方数据
